Foli Doce

Quick links to important sections

Foli Doce

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Foli Doce

What is Foli Doce? Defining the Combination Vitamin

Property Description
Active Ingredients Cyanocobalamin (Vitamin B12), Folic Acid (Vitamin B9)
Pharmacological Class Vitamins and Antianemic Preparations
Form Oral Tablets (Comprimidos), Injectable Solution
Common Use Addressing and preventing B12 and Folate deficiency states
Origin Synthetic/Derived

Foli Doce: Composition, Origin, and Unique Positioning

Foli Doce is a prescription pharmaceutical preparation, often supplied as oral tablets (comprimidos) and is classified as a combination product within the Vitamins and Antianemic Preparations pharmacological group. Its two active components are the synthetic/derived forms of two essential water-soluble B vitamins: Cyanocobalamin (Vitamin B12) and Folic Acid (Vitamin B9).

The co-formulation is strategically important: the metabolism of Folic Acid is dependent on the adequate presence of Vitamin B12. This combined approach is used for providing comprehensive nutritional support, which is critical since the body cannot synthesize these vitamins on its own. Unlike single-vitamin supplements, Foli Doce is specifically positioned to manage the interplay between these two nutrients, often managing the nutritional needs of patient groups such as women of childbearing age.


Function and General Purpose

The mechanism of Foli Doce centers on the provision of these essential cofactors necessary for DNA synthesis, the fundamental process required for all new cell growth and division. This combined approach relates to the management of macrocytic anemias.

The primary physiological role of the preparation is to support hematopoiesis, the proper production and maturation of Red Blood Cells (RBCs). The overall purpose is to address or prevent deficiency states associated with insufficient intake or absorption of both Vitamin B12 and Folic Acid, ensuring proper blood formation and supporting the integrity of the nervous system.

What side effects are possible with Foli Doce?

Possible Side Effects and Safety Information

The safety profile for the combination of Cyanocobalamin (Vitamin B12) and Folic Acid (Vitamin B9) is structured around official regulatory classifications, including frequency, body systems affected, and critical safety constraints. The majority of documented adverse reactions relate to the Cyanocobalamin component.


Officially Documented Adverse Reactions

Adverse reactions are classified across several System Organ Classes (SOC). Serious reactions related to the Immune System include anaphylactic shock and death, which have been reported following parenteral administration, and are typically classified as Rare or Incidence Not Known in official documents. Other serious effects within the Cardiac and Vascular SOC include reports of pulmonary edema, congestive heart failure, and peripheral vascular thrombosis, sometimes noted as occurring early in treatment.

Less frequently, reactions may involve the Gastrointestinal system (e.g., mild transient diarrhea) and Dermatological system (e.g., itching and transitory exanthema).


Critical Safety Constraints and Considerations

A paramount regulatory constraint involves the use of Folic Acid, as doses greater than 0.1 mg per day may mask the hematological signs of an underlying Vitamin B12 deficiency while allowing progressive and irreversible neurological damage to continue. The product is officially contraindicated in patients with early Leber’s disease due to the risk of severe optic atrophy. Furthermore, specific cautions exist for certain populations: premature neonates and patients with impaired kidney function face risks from aluminum accumulation if the medicine is administered parenterally for prolonged periods.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Foli Doce (Cyanocobalamin and Folic Acid) is characterized by a low acute toxicity risk, consistent with its components being water-soluble B vitamins.

Documented Overdose Manifestations

Acute overdose of Cyanocobalamin is generally well-tolerated and not associated with specific toxic symptoms in regulatory labeling; excess is typically excreted renally. Manifestations, when they occur, are primarily linked to exposure to very high or chronic doses of Folic Acid. These documented effects are typically mild and may include pruritus, rash, malaise, sleep disturbance, or gastrointestinal disturbance. Regulatory documents do not cite any acute severe or life-threatening outcomes resulting directly from an overdose of these components.

Required Emergency Actions

In the event of a suspected or known overdose, the mandated regulatory instruction is to seek immediate medical attention. This action is required for clinical assessment.

Management for this overdose is defined as symptomatic and supportive treatment. Official prescribing information states that no specific antidote is known for overdose of either Cyanocobalamin or Folic Acid. Clinical monitoring is required to observe vital signs and manage any potential manifestations that may occur. No population-specific overdose considerations are explicitly detailed in official labeling.

Therapeutic Uses of Foli Doce

What Foli Doce Treats: Main Uses and Benefits

Foli Doce is used for symptomatic management in areas where short-term symptomatic assistance is needed.

The medicine is applied across therapeutic domains where additional symptomatic support is needed, and is relevant for managing symptom clusters associated with conditions involving episodic or fluctuating manifestations or conditions associated with acute or disruptive episodes. It is commonly used across conditions presenting with acute episodes to help address symptom clusters that may appear suddenly or fluctuate, including symptoms related to physical discomfort. It supports the patient during difficult episodes by easing distress. The use of Foli Doce is relevant in contexts marked by increased discomfort or tension. It provides support during periods of heightened functional strain and is relevant for easing symptoms when they become temporarily overwhelming.

Quick Fact: Foli Doce is commonly used across conditions presenting with acute episodes to help address symptom clusters that may appear suddenly or fluctuate.

Eligibility and Restrictions for Use

Who Can and Cannot Use Foli Doce? Official Regulatory Information

The eligibility profile for Foli Doce (Cyanocobalamin/Folic Acid) is defined by regulatory mandates to ensure patient safety, particularly concerning the diagnostic integrity of megaloblastic anemia.

Populations and Conditions Governing Eligibility

Category Official Regulatory Statement
Populations Allowed Adults with confirmed Vitamin B12 and/or Folate deficiency states; Patients with macrocytic anemia secondary to deficiency; Women of childbearing age for prophylactic folate supplementation.
Absolute Contraindications Patients with known hypersensitivity to Cyanocobalamin, Folic Acid, or Cobalt; Patients with undiagnosed megaloblastic anemia or macrocytic anemia of unknown etiology; Patients with Leber's disease.
Age-Related Rules Use is generally not established or not recommended for children under 12 years; Specific injectable formulations may be restricted in infants and neonates due to excipient risks.
Physiological Status Use is generally permitted during both pregnancy and lactation when indicated for deficiency states.
Use Restrictions Patients with severe renal impairment require special caution; Caution is advised for patients with certain folate-dependent malignancies.

These criteria establish absolute non-eligibility for patients where Folate could mask an underlying B12 deficiency, a risk that regulatory bodies strictly prohibit. Eligibility is restricted to populations addressing a verified or high-risk deficiency state.

What should I know about interactions with other medicines?

The official interaction profile for Foli Doce is defined by the documented effects of its active components, Cyanocobalamin and Folic Acid, on the efficacy and exposure of co-administered medicines. A primary restriction noted in regulatory documents is the prohibition against co-administration with Methotrexate, as Folic Acid can pharmacodynamically counteract its intended therapeutic effect.

Interactions involving certain anticonvulsant agents, including Phenytoin, Phenobarbital, and Primidone, are explicitly documented. Co-administration of Folic Acid is noted to reduce the plasma concentration of these medicines, a pharmacokinetic effect that may compromise the therapeutic benefit of the anticonvulsant agent.

Interactions that compromise the systemic exposure of the Cyanocobalamin component are also officially documented. Substances such as Colchicine, Neomycin, and Para-aminosalicylic acid (PAS) may impair the intestinal absorption process, resulting in reduced availability of Vitamin B12.

Furthermore, official regulatory documents note other pharmacodynamic interferences. Chloramphenicol may reduce the hematopoietic response associated with Cyanocobalamin, and Folic Acid may interfere with the anti-folate effect of Pyrimethamine.

This structure establishes mandatory restrictions, particularly the contraindicated combination with Methotrexate, and identifies substances with documented effects on co-administered drug levels.

Mechanism of Action

The mechanism of Foli Doce is the provision of Cyanocobalamin ( B12) and Folic Acid ( B9), which function as essential cofactors to enable key enzyme activity. This action directly restores the necessary building blocks (purines and thymidines) for DNA synthesis via enzymes like Thymidylate Synthase and Methionine Synthase, which is necessary for the proper division and maturation of cells. The physiological consequence is the normalization of erythrocyte precursor cell maturation in the hematopoietic system.

Furthermore, the B12 component mediates the formation of S-adenosylmethionine (SAM), the central methyl donor required for the biosynthesis of lipids that form the myelin sheath. This specific action facilitates the synthesis of lipids necessary for the structure of the central and peripheral nervous systems. The combination reflects a direct mechanistic synergy in the One-Carbon Metabolism pathway: B12 is essential for converting circulating folate into its active form, preventing the Folate Trapping Hypothesis. This coordinated action couples the mechanism for DNA replication with the mechanism for neuronal structural maintenance, reflecting their shared metabolic dependence.

Dosage and Administration Information

How to Use Foli Doce: Administration Guidelines

Foli Doce (Folic Acid) is typically administered following established protocols. These guidelines describe the administration routes, standard dosing ranges, and specific conditions for intake.


Administration Details

Element Guideline Overview
Route of Administration Primarily Oral (PO). Parenteral (IM, IV, SC) use is generally reserved for cases where oral administration is not feasible or for severe malabsorption.
Standard Dosing Therapeutic: Up to 1 mg daily for adults and children. Adult Maintenance: Typically 0.4 mg daily.
Frequency Generally Once Daily (OD). Certain specialty regimens, such as for prophylaxis, may follow a weekly pattern.
Intake Condition The medication can be taken with or without food.

Procedural and Population-Specific Instructions

The following patterns define the procedural steps and use in different patient groups:

  • Preparation: Oral tablets should be swallowed whole with water. They are not intended to be crushed or chewed.
  • Age-Specific Rules: Dosing adjustments apply to infants (e.g., 0.1 mg daily for maintenance) and pregnant women (e.g., 0.8 mg daily for maintenance).
  • Missed Dose: If a dose is missed, standard practice is to skip the missed dose and resume the regular schedule with the next dose; the dose should not be doubled to compensate.
  • Duration: The course of treatment, such as for deficiency, typically continues until hematological parameters normalize, which may take up to four months, or it may be continued long-term for chronic conditions.

These parameters structure the course of use, defining the amount, frequency, and manner in which the drug is administered.

Recent Clinical Evidence

Evidence for Use in Addressing Nutritional Deficiency States

Research for the fixed combination of Cyanocobalamin (B12) and Folic Acid (B9) has explored the medicine's role in addressing established nutritional deficiencies. Studies include Randomized Controlled Trials (RCTs) and systematic reviews, primarily involving individuals who presented with low vitamin levels due to insufficient intake or absorption. These studies monitored changes in key blood parameters and reported measurements showing a shift in laboratory values, such as hemoglobin and Mean Corpuscular Volume (MCV), during the study period. Success was generally measured by the medicine's association with the restoration of established blood formation markers and the correction of low serum biomarker concentrations. Evidence quality varies, and there is limited information that directly compares the fixed combination against separate single-vitamin therapies in all deficiency subgroups.


Evidence for Use in Preventing Neural Tube Defects

Evidence for this specific use is largely derived from extensive research on the Folic Acid component. This research has explored the use of the vitamin in women of childbearing age around the periconceptional period. These studies monitored the incidence rates of Neural Tube Defects (NTDs) in newborns and changes in maternal folate status. Reported outcomes showed patterns related to elevated maternal serum and RBC folate concentrations following consistent administration. The specific role of the B12 component in preventing NTDs, beyond supporting the function of folate, is not fully established by dedicated fixed-combination RCTs.


Understanding Research Gaps and Uncertainty

Research has explored the medicine's influence on correcting metabolic markers like Homocysteine (tHcy). While trials reported measurements showing a decrease in tHcy concentrations, findings were mixed regarding whether this biomarker change consistently translates into predictable improvements in major clinical outcomes. Furthermore, high-quality RCTs specifically investigating the long-term neurological impact of the fixed combination are scarce. The evidence quality varies across studies, and data for certain specific patient groups, such as those with rare malabsorption disorders, remain insufficient.

Key Studies & References

  1. Megaloblastic Anemia - StatPearls - NCBI Bookshelf
  2. Cyanocobalamin - StatPearls - NCBI Bookshelf
  3. Current Guidelines for Folic Acid Supplementation (Appendix A Table 2) - NCBI Bookshelf (AHRQ)
  4. Effects of folic acid with vitamin B12/vitamin B6 intervention on serum homocysteine metabolism and complications in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
  5. Folate deficiency: MedlinePlus Medical Encyclopedia - NIH
  6. ATC code B03B: Vitamin B12 and folic acid (WHO ATC/DDD Index)

Frequently Asked Questions (FAQ)

Common questions about Foli Doce (FAQ)

Q: Is Foli Doce considered a vitamin supplement or a prescription medication?

A: According to official regulatory classifications, Foli Doce is categorized as a prescription pharmaceutical preparation, or a drug. It falls within the pharmacological group known as Vitamins and Antianemic Preparations. It is not generally marketed as an over-the-counter vitamin supplement.

Q: What specific conditions or deficiencies is Foli Doce used to prevent?

A: Foli Doce is primarily indicated for the prevention and treatment of vitamin B12 and/or folate deficiencies. It is also indicated for the prophylactic prevention of neural tube defects in women of childbearing age.

Q: How quickly should one expect to notice any effects after starting Foli Doce?

A: Initial response is often tracked by changes in blood counts, such as reticulocyte counts, which are typically checked between the 5th and 7th days of therapy. While these are the earliest measurable signs of the body's response, the time it takes to notice perceivable effects like reduced fatigue may vary widely based on individual circumstances.

Q: Is it normal to feel slightly nauseous when first starting to take Foli Doce?

A: Official information for the components of Foli Doce notes that gastrointestinal side effects have been reported. These can include mild transient diarrhea, general stomach upset, and in some cases, nausea. If symptoms are persistent or severe, professional medical consultation is advised.

Q: What are the non-serious side effects associated with Foli Doce?

A: Officially documented non-serious effects include mild transient diarrhea, itching, and transitory exanthema (a temporary rash). The full safety information should be reviewed, and any unexpected reactions should be discussed with a healthcare professional.

Q: What are the signs of an allergic reaction to Foli Doce's ingredients?

A: Serious allergic reactions, including anaphylaxis, have been reported with the components of Foli Doce. Signs of a severe reaction can include hives, rash, severe itching, swelling of the mouth, face, or throat, wheezing, and trouble breathing.

Q: How does Foli Doce compare to just taking a high-dose folic acid supplement?

A: The combination product is used because regulatory warnings exist regarding the use of high-dose folic acid alone. Taking high-dose folic acid can mask the blood-related symptoms of an underlying Vitamin B12 deficiency while potentially allowing irreversible neurological damage to continue to progress.

Q: Why is Foli Doce sometimes prescribed for people taking methotrexate?

A: Regulatory documents generally state that folic acid can counteract the therapeutic effect of methotrexate. However, in specific clinical protocols, a folic acid product may be used for 'rescue therapy' to limit toxicity. Due to this complex relationship, co-administration is strictly managed under physician guidance for specific clinical reasons.

Q: What is the difference between folate and the folic acid found in Foli Doce?

A: Folate is the general term for Vitamin B9 found naturally in foods. Folic acid is the specific synthetic form of Vitamin B9 that is typically used in pharmaceutical preparations like Foli Doce and in fortified foods.

Q: Does Foli Doce help with low energy levels or general tiredness?

A: The medicine is indicated to correct B12 and folate deficiencies. Since these deficiencies can lead to anemia, which often causes fatigue and generalized weakness, correcting the deficiency is the therapeutic goal for managing these symptoms.

Q: Can Foli Doce cause changes in urine color or smell?

A: Regulatory information indicates that, like other water-soluble B vitamins, excess amounts are rapidly excreted. This process is known to sometimes cause the urine to appear bright yellow or slightly discolored.

Q: How long does Foli Doce stay in your system after you stop taking it?

A: Most of the administered dose of the water-soluble components is rapidly eliminated via the urine, with a large portion excreted within 48 hours. However, a portion of Vitamin B12 is retained by the body, primarily stored in the liver.

Q: Do any specific foods need to be avoided while taking Foli Doce?

A: The medication can generally be taken with or without food. Some patient-level information suggests that certain items like whole grain breads, coffee, and tea may interfere with absorption, but official labels do not typically mandate universal food restrictions.

Q: Does alcohol consumption affect the absorption or effectiveness of Foli Doce?

A: Official warnings note that heavy alcohol intake over a long period (e.g., more than two weeks) may cause malabsorption of Vitamin B12. General patient guidance may suggest limiting alcoholic beverages, particularly due to this risk.

Q: Is there a recommended time of day (morning or evening) to take Foli Doce?

A: The drug can be taken with or without food. Patient instructions often recommend taking the dose at the same time each day to help establish a routine. However, the regulatory labeling does not mandate a specific time of day (morning vs. evening) for effectiveness.

Q: Can older adults safely take Foli Doce for B12 deficiency?

A: The product is indicated for use in adults with confirmed deficiencies, a population that includes older adults. While specific geriatric safety information may vary by formulation, the use in older adults is generally based on the individual's specific health status and diagnosis.

Q: Are there any long-term effects from taking Foli Doce continuously?

A: Treatment may be necessary long-term for certain chronic conditions, such as pernicious anemia. Long-term use requires periodic monitoring due to the risk that folic acid could mask a developing B12 deficiency, potentially leading to neurological damage.

Q: Does taking Foli Doce affect blood test results other than B12 and folate levels?

A: Yes, regulatory documents note that the drug may affect diagnostic blood assays for B12 and folate. Other blood parameters, such as hematocrit, reticulocyte count, and iron levels, are typically monitored during treatment.

Q: Is the type of Vitamin B12 in Foli Doce (Cyanocobalamin) easily absorbed?

A: The oral form of Cyanocobalamin is the most commonly used synthetic B12. Its absorption requires intrinsic factor for active transport. The oral route is often restricted to patients without intrinsic factor deficiency, as absorption is reduced in certain malabsorption conditions.

Q: Can Foli Doce cause any skin-related side effects, like rashes?

A: Yes, officially documented skin reactions include generalized itching and exanthema (rash). A widespread rash or hives can also be a sign of a serious allergic reaction.

Q: How long does it typically take for B12 levels to improve while on Foli Doce?

A: Serum B12 levels are typically assessed one month after treatment is started. This time point is used by healthcare professionals to check for improvement and ensure the treatment is effectively raising the body's B12 concentration.

Q: Is Foli Doce suitable for individuals following a vegetarian or vegan diet?

A: Because Vitamin B12 is not found in foods of plant origin, the official label notes that individuals on a vegetarian or vegan diet are at risk for deficiency. The labeling notes that individuals on such a diet are at risk for B12 deficiency and may require therapeutic intervention.

Q: Is Foli Doce a replacement for a balanced diet rich in B vitamins?

A: Official patient guidance emphasizes that while the product treats deficiencies, it is best to get vitamins and minerals from a well-balanced diet whenever possible. Foli Doce is intended to supplement and correct deficiencies, not to replace a healthy diet.

Q: Does the body excrete excess folic acid and B12 from Foli Doce?

A: Yes, as water-soluble vitamins, both B12 and folic acid are readily eliminated. Excess amounts are rapidly excreted in the urine, with a large portion eliminated within 48 hours of administration.

Q: Is it possible to be allergic to the inactive ingredients in Foli Doce?

A: While allergies to the active ingredients are noted, the label also advises informing a healthcare professional of all allergies, including those to inactive components (excipients) or dyes in the product.

Q: Are there any known effects of Foli Doce on driving or operating machinery?

A: Some B-vitamin combination products may cause side effects like drowsiness. Precautions may be necessary if side effects like drowsiness occur. Activities requiring full alertness, such as driving or operating machinery, should be avoided until one knows how the medication affects them.

Q: Why is Foli Doce recommended to be started one month before conception?

A: Official guidelines recommend starting folic acid at least one month before conception. This timing is critical because the neural tube, which prevents defects like spina bifida, forms very early in pregnancy.

Q: Does Foli Doce provide all the necessary B vitamins, or just B9 and B12?

A: Foli Doce is formulated as a specific combination product. Its active ingredients are Cyanocobalamin (Vitamin B12) and Folic Acid (Vitamin B9). It does not contain the full spectrum of B vitamins.

How should Foli Doce be stored and disposed of?

How to Store and Dispose of Foli Doce?

The storage and disposal instructions for Foli Doce (Cyanocobalamin and Folic Acid tablets) are defined by regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Storage Requirement Specification
Temperature Store at Controlled Room Temperature (20 C to 25 C). Do not freeze.
Container Keep the tablets in the original, tightly closed container with a child-resistant closure.
Protection The product must be protected from light and moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Foli Doce must be disposed of according to local regulations for pharmaceutical waste. The tablets must not be flushed down a toilet or placed into household wastewater, which helps protect the environment. Local pharmacy or community take-back programs are often recommended for correct disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Foli Doce found in:

A-Z Index: